Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2025)

Historic Work In Process for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $29.2 million.

  • Ultragenyx Pharmaceutical's Work In Process rose 4391.8% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 4391.8%. This contributed to the annual value of $22.0 million for FY2024, which is 1648.02% up from last year.
  • Ultragenyx Pharmaceutical's Work In Process amounted to $29.2 million in Q3 2025, which was up 4391.8% from $19.8 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Work In Process ranged from a high of $29.2 million in Q3 2025 and a low of $6.8 million during Q1 2021
  • Its 5-year average for Work In Process is $17.5 million, with a median of $18.5 million in 2023.
  • Its Work In Process has fluctuated over the past 5 years, first surged by 7675.07% in 2022, then plummeted by 2176.86% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Work In Process stood at $10.5 million in 2021, then skyrocketed by 66.47% to $17.5 million in 2022, then rose by 7.85% to $18.9 million in 2023, then increased by 16.48% to $22.0 million in 2024, then surged by 32.87% to $29.2 million in 2025.
  • Its Work In Process was $29.2 million in Q3 2025, compared to $19.8 million in Q2 2025 and $22.9 million in Q1 2025.